Therapeutic Conjugates for Targeted Cellular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic compounds, such as antiviral and chemotherapeutic agents, face challenges due to low selectivity, leading to toxicity in normal tissues and restricted cellular uptake by complex membrane systems, limiting their effectiveness.
Innovation Solution
Development of conjugates that utilize specific receptors for targeted delivery, such as folate-based conjugates for cancer cells and galactose-based conjugates for hepatocytes, along with peptide-based transporters like ANTENNAPEDIA and HIV Tat peptides, to facilitate the transport of therapeutic molecules across cellular membranes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents are used, then broad coverage is achieved, but selectivity is low resulting in high toxicity to normal tissues
Solution Approach 1:
The patent uses cell-penetrating peptides (CPPs) as intermediary carriers to deliver therapeutic compounds into cells. The CPPs facilitate selective cellular uptake of the therapeutic agents while minimizing non-specific distribution to normal tissues, thereby improving selectivity and reducing toxicity.
Solution Approach 2:
The patent modifies the physical and chemical parameters of therapeutic compounds by conjugating them with cell-penetrating peptides. This changes the cellular uptake characteristics from passive diffusion to active peptide-mediated transport, improving selectivity for target cells while reducing off-target toxicity.
2Reliability
If conventional compounds are used, then broad applicability is achieved, but cellular uptake is restricted by complex membrane systems
Solution Approach 1:
Cell-penetrating peptides serve as mediators that interact with cell membrane systems to facilitate compound entry. These peptides can traverse the complex membrane barriers through various mechanisms including endocytosis, membrane disruption, or translocation, thereby enabling efficient cellular uptake of therapeutic compounds.
Solution Approach 2:
The patent creates composite structures by conjugating therapeutic compounds with cell-penetrating peptides. This composite approach combines the therapeutic activity of the compound with the membrane-transverse capability of the peptide, enabling efficient cellular uptake while maintaining therapeutic function.
3Productivity
If lipid carriers are used to improve cellular delivery, then transport efficiency is enhanced, but device complexity increases
Solution Approach 1:
The patent uses short peptide sequences (typically 5-50 amino acids) as temporary delivery vehicles. These peptides perform their function of facilitating cellular uptake and can be designed to be cleaved off or degraded after delivery, simplifying the overall system compared to complex lipid carrier structures.
Solution Approach 2:
The patent changes the carrier type from lipids to peptides, altering the fundamental parameters of the delivery system. Peptides offer simpler structures, easier synthesis, and better biocompatibility compared to lipid carriers, while maintaining or improving transport efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the delivery of therapeutic compounds to specific cell types, reducing toxicity and improving bioavailability, pharmacodynamics, and pharmacokinetics, while allowing for efficient cellular uptake without the need for lipids, thereby improving treatment efficacy.
Implementation Method 1
The use of folic acid based conjugates to transport exogenous compounds across cell membranes can provide a targeted delivery approach
Implementation Method 2
galactose-based conjugates for hepatocytes
Implementation Method 3
peptide-based transporters like ANTENNAPEDIA and HIV Tat peptides, to facilitate the transport of therapeutic molecules across cellular membranes
Data Source
AI summary
This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including cholesterol derived conjugates of biologically active compounds, including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNAzymes, allozymes, antisense, dsRNA, siNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys and aptamers.